( oster on Sunday April 15 2007 titled...)Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR,Health

oster on Sunday, April 15, 2007, titled, "Tanespimycin (17-AAG, KOS-953): No Effects on QTc Interval Using Two Formulations" (abstract #1544). A second poster, entitled "Preclinical Safety Profile of Tanespimycin (KOS-953) -- a Heat Shock Protein 90 (Hsp90) Inhibitor" (abstract #1568) reported on preclinical toxicology studies with tanespimycin and confirmed that in these studies tanespimycin had no adverse effect on QTc interval.

Results of Cardiac Monitoring Analyses

To evaluate whether tanespimycin had any effect on the QTc interval, patients in clinical trials of tanespimycin underwent ECG monitoring prior to the study, before dosing, near the expected time of maximal plasma concentrations within 20 minutes after the infusion, as well as at the end of the study. ECG intervals were measured by a dedicated cardiologist at Memorial Sloan-Kettering Cancer Center (MSKCC) or by a central cardiologist at an independent third-party laboratory.

In trials conducted by MSKCC, under the auspices of CTEP, tanespimycin was administered in an egg-phospholipid/4% DMSO formulation. In trials of tanespimycin sponsored by Kosan, tanespimycin was administered in a Cremophor-based formulation. There was no evidence in any of these trials that tanespimycin prolonged the QTc interval (a prolongation of the interval can lead to ventricular arrhythmia).

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multipl
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference